Gemcitabine en es it fr

Gemcitabine Brand names, Gemcitabine Analogs

Gemcitabine Brand Names Mixture

  • No information avaliable

Gemcitabine Chemical_Formula


Gemcitabine RX_link

Gemcitabine fda sheet

Gemcitabine FDA

Gemcitabine msds (material safety sheet)

Gemcitabine MSDS

Gemcitabine Synthesis Reference

No information avaliable

Gemcitabine Molecular Weight

263.198 g/mol

Gemcitabine Melting Point


Gemcitabine H2O Solubility


Gemcitabine State


Gemcitabine LogP


Gemcitabine Dosage Forms

Lyophilized powder for injection

Gemcitabine Indication

For the first-line treatment of patients with metastatic breast cancer, locally advanced (Stage IIIA or IIIB), or metastatic (Stage IV) non-small cell lung cancer and as first-line treatment for patients with adenocarcinoma of the pancreas.

Gemcitabine Pharmacology

Gemcitabine is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA. They prevent these substances becoming incorporated in to DNA during the "S" phase (or DNA synthesis phase of the cell cycle), stopping normal development and division. Gemcitabine blocks an enzyme which converts the cytosine nucleotide into the deoxy derivative. In addition, DNA synthesis is further inhibited because Gemcitabine blocks the incorporation of the thymidine nucleotide into the DNA strand.

Gemcitabine Absorption


Gemcitabine side effects and Toxicity

Myelosuppression, paresthesias, and severe rash were the principal toxicities, LD50=500 mg/kg (orally in mice and rats)

Gemcitabine Patient Information

General �� Patients receiving therapy with Gemzar should be monitored closely by a physician
experienced in the use of cancer chemotherapeutic agents. Most adverse events are reversible and
do not need to result in discontinuation, although doses may need to be withheld or reduced.
There was a greater tendency in women, especially older women, not to proceed to the next

Laboratory Tests �� Patients receiving Gemzar should be monitored prior to each dose with a
complete blood count (CBC), including differential and platelet count. Suspension or
modification of therapy should be considered when marrow suppression is detected.

Gemcitabine Organisms Affected

Humans and other mammals